NoBsRx Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.6/10
Best for: fully published, flat-dose compounded GLP-1 pricing with the dispensing pharmacies named
Price is where NoBsRx scores best in our breakdown.
Semaglutide
Tirzepatide
What the monthly price covers
Medication
Not disclosed
Provider visits
Not disclosed
Shipping
Not disclosed
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
NoBsRx is a telehealth platform that connects you with licensed providers for compounded GLP-1 treatment, filled by state-licensed 503A pharmacies it names in its terms. Every program price is posted before you start: injectable semaglutide $179/mo, oral semaglutide $199/mo and injectable tirzepatide $249/mo, with low-dose programs from $140/mo and no price change as your dose rises. Prepaid 12-, 24- and 52-week terms cost less per month.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Vetted alternatives to NoBsRx
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
NoBsRx at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $140/mo (Pricing page 'Low-dose injectable semaglutide program': '$140/ monthly'; 12 weeks $409.)
- Pricing model
- Flat — dose increases don't raise the monthly price
- FDA status
- No FDA warning letter on record
How we scored NoBsRx
Each dimension is scored algorithmically from NoBsRx’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
8.3/10At $140/mo, NoBsRx runs about 17% below the $170 median for GLP-1 providers. Pricing is flat across doses, so there is no escalation markup as you titrate up.
Effectiveness25%
8.2/10NoBsRx offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes. An oral/needle-free option is offered for patients who avoid injections.
User Experience15%
7.2/10Online intake and platform experience; 8 platform features disclosed.
Trust & Safety15%
7.7/10Core details confirmed by our editors; no FDA warning letters on file; dispenses through an accredited compounding pharmacy.
Accessibility10%
6.1/10NoBsRx's exact state footprint isn't published — confirm coverage in your state before signing up.
Support10%
5.9/10NoBsRx provides standard clinician follow-up; no extended coaching or community program is disclosed.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this NoBsRx review
Last checked September 2026- Confirmed current pricing across 6 dose/plan tiers
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
What to expect when you sign up with NoBsRx
We walked NoBsRx’s public signup flow in September 2026 to document the process — the steps, pricing transparency, and what’s required — before you commit. (We don’t create accounts, enter medical information, or check out; this is the observable funnel, not a prescribing outcome.)
- 1Prices come first: the pricing page lists all six programs (standard and low-dose, oral and injectable) with monthly and prepaid prices, and asks for no email or signup to see them.
- 2'Start Your Intake' opens a short page with a treatment disclaimer and two choices, 'Microdosing' or 'Macrodosing' (labeled 'Best for weight loss'), plus a sleep program marked 'Coming soon'.
- 3Either choice opens a new tab on the intake platform of OpenLoop, a partner telehealth company, which starts with a 'Security Check' reCAPTCHA box before any question. We stopped at that gate.
- The price list is unusually complete for a compounded GLP-1 seller: all six programs show a monthly rate and a prepaid 12-week total, the three standard programs add 24- and 52-week totals, and every card says 'No dose-based price changes'.
- The intake runs on OpenLoop's own site, not on nobsrx.com. NoBsRx's privacy policy says clinical information is handled by partner platforms 'such as Tellescope/OpenLoop or equivalent'.
- The intake platform's cancellation policy for NoBsRx says 'Our billing operates on a 28-day cycle', so a monthly plan works out to 13 charges a year. We could not reach the cart to see this on an order summary.
- NoBsRx's pricing pages say 'What's published is what you pay', but its subscription terms say medication, dispensing and shipping charges are 'not included in the NoBsRx platform subscription'. Ask what your program price covers before you pay.
- The two cancellation instructions disagree: NoBsRx's subscription terms say to email support because there is no self-service option, while the intake platform's policy says to cancel in the Patient Portal.
- Prepaid terms renew automatically 'for successive periods of the same duration', so a 52-week prepay rolls into another 52 weeks unless you cancel first.
- No company legal name, business address or prescribing medical group is published; the four dispensing pharmacies are the only named partners on the GLP-1 side.
- We did not take the medication, so nothing here describes treatment results.
NoBsRx customer support
- Phone
- 1-808-518-3894
- support@nobsrx.com
- Hours
- No hours published; email replies promised within 1–2 business days
GLP-1 medications NoBsRx offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Pricing
Prices re-verified
Pricing page: '$179/ monthly', flagged 'Popular'. Prepaid terms: 12 weeks $499, 24 weeks $999, 52 weeks $1,899. 'No dose-based price changes'.
Pricing page: '$199/ monthly'. Prepaid terms: 12 weeks $579, 24 weeks $1,149, 52 weeks $2,199. Oral dosage form not specified.
Pricing page: '$249/ monthly'. Prepaid terms: 12 weeks $649, 24 weeks $1,289, 52 weeks $2,599. 'No dose-based price changes'.
Pricing page 'Low-dose injectable semaglutide program': '$140/ monthly'; 12 weeks $409.
Pricing page 'Low-dose oral semaglutide program': '$179/ monthly'; 12 weeks $409.
Pricing page 'Low-dose injectable tirzepatide program': '$140/ monthly'; 12 weeks $409.
Ready to get started?
Plans and promotions change often — check NoBsRx's current pricing and active discounts before you decide.
What we like
- Every program price is posted before intake with no email wall: semaglutide from $179/mo, tirzepatide $249/mo
- Same price at every dose: each program card reads 'No dose-based price changes'
- Low-dose injectable semaglutide or tirzepatide at $140/mo, plus an oral semaglutide option
- Its terms name the four state-licensed pharmacies that may fill your prescription, with addresses and phone numbers
- LegitScript seal is served from LegitScript's own image server, not self-hosted
- Publishes a support phone number and email, with email replies promised within 1–2 business days
- States plainly that its compounded semaglutide and tirzepatide are not FDA-approved
Watch-outs
- No company legal name, business address or governing state is published anywhere on the site
- The prescribing medical group is not named; the site says only that independent licensed providers review your intake
- Plans are labeled monthly, but the intake's cancellation policy says charges run every 28 days: 13 charges a year, not 12
- Its subscription terms say medication, dispensing and shipping fees are outside the platform fee, at odds with 'what's published is what you pay'
- Cancellation instructions conflict: NoBsRx says email support (no self-service), the intake's policy says use the patient portal
- Platform fees are non-refundable once a clinical review starts, even if you are found ineligible
- State availability is not published; the site says programs are not available in all states
- Compounded semaglutide and tirzepatide are not FDA-approved
Is NoBsRx worth it? Our verdict
NoBsRx positions itself around one thing: fully published, flat-dose compounded GLP-1 pricing with the dispensing pharmacies named. It runs $140/month, flat across every dose — toward the affordable end of the market. Its standout is a needle-free oral option, which very few providers offer.
NoBsRx rounds out its offering with Microdose Options, Flat Dose Pricing, and 503A Pharmacy.
How much NoBsRx actually costs
- Compounded semaglutide — $179/month
- Compounded semaglutide — $199/month
- Compounded tirzepatide — $249/month
- Compounded semaglutide — $140/month
- Compounded semaglutide — $179/month
- Compounded tirzepatide — $140/month
That puts NoBsRx below the roughly $170 median ongoing price across the GLP-1 providers we track — a real cost advantage.
Yucca Health (about $146/month) is one of the closest alternatives to weigh NoBsRx against.
Medications: what NoBsRx prescribes
NoBsRx prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro) — the two molecules with the strongest published weight-loss trial outcomes. The medication is compounded at a licensed pharmacy rather than sold as a brand pen, which is what keeps the price down. The trade-off is the one every compounded provider shares: compounded drugs aren't FDA-approved as finished products.
NoBsRx's needle-free oral option is a real draw if you've been avoiding a GLP-1 because of injections. Just set expectations on the science: oral and buccal delivery of these peptides is far less studied than the injectable versions the trials used, so treat it as a convenience option rather than a proven equal to the shot.
Who NoBsRx is best for — and who should skip it
A good fit if you…
- are focused on the lowest ongoing monthly cost.
- are needle-averse and want a non-injectable option.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen.
- need to bill insurance — like most of this market, it's cash-pay.
Trust, safety, and medical oversight
NoBsRx dispenses through an accredited compounding pharmacy. We found no FDA warning letters on file for the provider. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation — we explain how in our scoring methodology.
Bottom line
NoBsRx earns its place on the shortlist mainly on price: at $140/month it's one of the more affordable ways to stay on a GLP-1, without obvious corners cut on access or oversight.
The Bottom Line
Price is where NoBsRx scores best in our breakdown.
Ready to start with NoBsRx?
Starting at $140/month. See current pricing and start your free consultation.
NoBsRx might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this NoBsRx review:
Sources & methodology — as of September 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See NoBsRx's current pricing
Plans start at $140/month. Start your free consultation to check eligibility and today's price.